Notable 52-Week Highs and Lows of the Day 10/26: (RTK) (QCOR) (BIIB) High; (HGSI) (TMO) (VCI) Low

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:

• Rentech, Inc. (NYSE: RTK) high of $1.62. Rentech ripped over 35 percent to its new high, as it's nitrogen subsidiary, Rentech Nitrogen Partners, issued the expected price and units to be issued in its IPO. Detail about that can be seen here.
  
  
• Questcor Pharmacueticals, Inc. (Nasdaq: QCOR) high of $41.14. Questcor is ripping over 23 percent to its new high following earnings. Questcor reported EPS of 37 cents on revenue of $59.8 million, beating views calling for EPS of 26 cents and revenue of $53.42 million.
  
  
• Biogen Idec Inc. (Nasdaq: BIIB) high of $119.75. Biogen Idec reported positive top-line results from CONFIRM, the second of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS). BG-12 met the CONFIRM study’s primary endpoint by significantly reducing annualized relapse rate (ARR) by 44 percent for BID (p< 0.0001) and by 51 percent for TID (p< 0.0001) versus placebo at two years.
  
  
• Panera Bread Co. (Nasdaq: PNRA) high of $138.58. Panera reported earnngs of 97 cents per share on revenue of $453 million, versus the consensus estimates for EPS of 94 cents and revenue of $446.97 million. Looking ahead, Panera sees fourth-quarter earnings of $1.39 to $1.41 per share, versus the consensus of $1.37. Fiscal 2012 earnings expected to be $5.38 to $5.48 per share, compared iwth the consensus of $5.29.

52-Week Low:

• Human Genome Sciences Inc. (Nasdaq: HGSI) low of $9.68. Human Genome reported a third-quarter loss of 45 cents per share and revenue of $34 million, versus consensus views calling for a loss of 39 cents per share and revenue of $37.31. Further, in previous guidance, originally provided in February 2011, Human Genome expected cash and investments at year-end 2011 to total between $550 million and $650 million. Human Genome now expects cash and investments at year-end 2011 to total between $440 million and $470 million, net of $79 million principal amount and interest paid upon maturity of the 2011 convertible debt.
  
  
• Thermo Fisher Scientific (NYSE: TMO) low of $47.77. Thermo Fisher reported third-quarter earnings of $1.07 per share and revenue of $2.97 billion, versus consensus views calling for earnings of $1.07 and slightly more robust revenue of $3.0 billion. However, looking ahead, Thermo Fisher sees fiscal 2011 earnings of $4.11 to $4.17, from prior guidance of $4.15 to $4.25, and below the consensus of $4.20. Additionally, Thermo lowered its fiscal 2011 revenue expectations from $11.79 to $11.89 billion to a range of $11.62 to $11.70 billion, and the consensus of $11.80 billion.
  
  
• Valassis Communications Inc. (NYSE: VCI) low of $14.71. Valassis had third-quarter earnings of 79 cents on revenue of $528.4 million, mixed to views calling for earnings of 73 cents and revenue of $571.1 million. Looking ahead, Valassis sees fiscal 2011 adjusted earnings of $2.56 per share, shy of the $2.82 expected. Shares moved 25 percent lower to the new mark on the session.
  
  
• Bemis Company, Inc. (NYSE: BMS) low of $27.35. Bemis is another earnings mover Wednesday, reported third quarter EPS of 56 cents and revenue of $1.36 billion, both missing views calling for EPS of 58 cents on revenue of $1.37 billion. Looking ahead, Bemis sees fourth-quarter earnings of 36 to 42 cents per share, versus the Street's 55 cents per share. For fiscal 2011, Bemis expects earnings of $1.90 to $1.96 per share, shy of the $2.11 consensus.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Chemung Financial (CHMG) Tops Q1 EPS by 44c